MX2020004902A - Derivados del acido oxoacridinilo acetico y metodos de uso. - Google Patents
Derivados del acido oxoacridinilo acetico y metodos de uso.Info
- Publication number
- MX2020004902A MX2020004902A MX2020004902A MX2020004902A MX2020004902A MX 2020004902 A MX2020004902 A MX 2020004902A MX 2020004902 A MX2020004902 A MX 2020004902A MX 2020004902 A MX2020004902 A MX 2020004902A MX 2020004902 A MX2020004902 A MX 2020004902A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- oxoacridinyl
- acetic acid
- acid derivatives
- sting
- Prior art date
Links
- 150000001242 acetic acid derivatives Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 102000014150 Interferons Human genes 0.000 abstract 1
- 108010050904 Interferons Proteins 0.000 abstract 1
- 150000002148 esters Chemical class 0.000 abstract 1
- 229940079322 interferon Drugs 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 150000003839 salts Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/06—Oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/86—Carbazoles; Hydrogenated carbazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/56—Ring systems containing three or more rings
- C07D209/80—[b, c]- or [b, d]-condensed
- C07D209/82—Carbazoles; Hydrogenated carbazoles
- C07D209/88—Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D219/00—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems
- C07D219/04—Heterocyclic compounds containing acridine or hydrogenated acridine ring systems with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
- C07D219/08—Nitrogen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
- C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
- C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Plural Heterocyclic Compounds (AREA)
- Indole Compounds (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (4)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201762588820P | 2017-11-20 | 2017-11-20 | |
| US201862631530P | 2018-02-16 | 2018-02-16 | |
| US201862723660P | 2018-08-28 | 2018-08-28 | |
| PCT/US2018/062021 WO2019100061A1 (en) | 2017-11-20 | 2018-11-20 | Oxoacridinyl acetic acid derivatives and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2020004902A true MX2020004902A (es) | 2020-09-09 |
Family
ID=66540425
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2020004902A MX2020004902A (es) | 2017-11-20 | 2018-11-20 | Derivados del acido oxoacridinilo acetico y metodos de uso. |
Country Status (13)
| Country | Link |
|---|---|
| US (2) | US10745358B2 (enExample) |
| EP (1) | EP3713920A4 (enExample) |
| JP (1) | JP7323539B2 (enExample) |
| KR (1) | KR20200100081A (enExample) |
| CN (1) | CN111630036B (enExample) |
| AU (1) | AU2018368789B2 (enExample) |
| BR (1) | BR112020009592A2 (enExample) |
| CA (1) | CA3079262A1 (enExample) |
| IL (1) | IL274796A (enExample) |
| MX (1) | MX2020004902A (enExample) |
| PH (1) | PH12020550652A1 (enExample) |
| SG (1) | SG11202004442VA (enExample) |
| WO (1) | WO2019100061A1 (enExample) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2019046511A1 (en) | 2017-08-31 | 2019-03-07 | Sperovie Biosciences, Inc. | COMPOUNDS, COMPOSITIONS AND METHODS FOR THE TREATMENT OF DISEASE |
| JP2022533390A (ja) * | 2019-05-16 | 2022-07-22 | スティングセラ インコーポレイテッド | オキソアクリジニル酢酸誘導体および使用方法 |
| EP3983078B1 (en) * | 2019-06-12 | 2023-11-15 | Ryvu Therapeutics S.A. | Next-generation modulators of stimulator of interferon genes (sting) |
| CN112442033A (zh) * | 2019-08-28 | 2021-03-05 | 迈德欣国际有限公司 | Sting通路调节剂及其用途 |
| CN112624972A (zh) * | 2019-09-24 | 2021-04-09 | 中国人民解放军军事科学院军事医学研究院 | 吖啶酮类化合物及医药用途 |
| RU2730530C1 (ru) * | 2019-10-29 | 2020-08-24 | Общество С Ограниченной Ответственностью "Научно-Технологическая Фармацевтическая Фирма "Полисан" | Новое химическое соединение L-лизина 9-оксоакридинил-10-ацетат, стимулирующее продукцию интерлейкина-24 и фактора некроза опухолей - бета |
| WO2021083383A1 (zh) * | 2019-11-02 | 2021-05-06 | 上海凌达生物医药有限公司 | 一类含氮稠环类sting调节剂类化合物、制备方法和用途 |
| CN111039849B (zh) * | 2019-12-26 | 2021-07-06 | 阜阳欣奕华材料科技有限公司 | 一种含有咔唑环类化合物的制备方法 |
| JPWO2021206158A1 (enExample) | 2020-04-10 | 2021-10-14 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3681360A (en) | 1971-04-09 | 1972-08-01 | Hoffmann La Roche | Antiviral substituted acridanones |
| JPH0867873A (ja) | 1994-08-29 | 1996-03-12 | Pioneer Electron Corp | 有機エレクトロルミネッセンス素子 |
| CA2213706A1 (en) | 1995-03-02 | 1996-09-06 | Yamanouchi Pharmaceutical Co., Ltd. | Novel quinuclidine derivative having tricyclic hetereo condensed ring |
| EP0857721A4 (en) | 1995-10-04 | 1999-07-28 | Eisai Co Ltd | ACRIDONE-BASED COMPOUNDS |
| US6333322B1 (en) * | 1996-03-13 | 2001-12-25 | Eisai Co., Ltd. | Nitrogen-containing tricyclic compounds and drugs containing the same |
| RU2118532C1 (ru) * | 1996-04-10 | 1998-09-10 | Олег Викторович Травкин | Противоинфекционное, противовоспалительное и противоопухолевое лекарственное средство |
| JPH11100373A (ja) * | 1997-09-26 | 1999-04-13 | Eisai Co Ltd | 新規フェノチアジン誘導体及びその医薬 |
| RU2197248C2 (ru) * | 2001-03-20 | 2003-01-27 | Травкин Олег Викторович | Лекарственный препарат, обладающий иммуномоделирующим, иммунокоррегирующим, противопаразитарным, противосклеротическим, противовирусным, противобактериальным, противогрибковым, противовоспалительным и противоопухолевым действием, и способ его приготовления |
| GB0113434D0 (en) | 2001-06-04 | 2001-07-25 | Amersham Pharm Biotech Uk Ltd | Quinacridone derivatives as labels for fluorescence detection of biological materials |
| GB0113435D0 (en) | 2001-06-04 | 2001-07-25 | Amersham Pharm Biotech Uk Ltd | Acridone derivatives as labels for fluorescence detection of target materials |
| JP2006526137A (ja) | 2003-05-28 | 2006-11-16 | ジーイー・ヘルスケア・ユーケイ・リミテッド | 内部標準の存在下で色素を標識することによる閉じた膜構造上の細胞表面タンパク質の示差分析 |
| CN1937994A (zh) * | 2004-04-06 | 2007-03-28 | 宝洁公司 | 角蛋白染色化合物、包含它们的角蛋白染色组合物以及它们的应用 |
| JP2006004736A (ja) | 2004-06-17 | 2006-01-05 | Sumitomo Chemical Co Ltd | 光電変換素子及び光電変換素子用色素 |
| WO2008021745A2 (en) | 2006-08-16 | 2008-02-21 | Itherx Pharmaceuticals, Inc. | Hepatitis c virus entry inhibitors |
| JP2008090130A (ja) * | 2006-10-04 | 2008-04-17 | Konica Minolta Medical & Graphic Inc | 感光性平版印刷版材料 |
| US20110039289A1 (en) | 2008-03-14 | 2011-02-17 | Pierre Graves | Fluorogenic peptides and their method of production |
| JP2009271403A (ja) | 2008-05-09 | 2009-11-19 | Konica Minolta Medical & Graphic Inc | 感光性平版印刷版材料および平版印刷版の製造方法 |
| JP5717959B2 (ja) | 2009-11-17 | 2015-05-13 | 株式会社Adeka | 芳香族スルホニウム塩化合物 |
| US8618125B2 (en) | 2011-01-14 | 2013-12-31 | Heptiva LLC | Composition comprising hepatic therapeutic active for treating liver diseases, certain cancers and liver health maintenance |
| WO2013022740A2 (en) | 2011-08-05 | 2013-02-14 | Corning Incorporated | Gpr35 ligands and the uses thereof |
| JP6082474B2 (ja) | 2013-09-30 | 2017-02-15 | 富士フイルム株式会社 | 感光性樹脂組成物、硬化膜の製造方法、硬化膜、有機ｅｌ表示装置および液晶表示装置 |
| KR20160065858A (ko) * | 2013-10-21 | 2016-06-09 | 드렉셀유니버시티 | 만성 b형 간염 바이러스 감염을 치료하기 위한 스팅 효능제의 사용 |
| CN103709122B (zh) | 2013-11-29 | 2016-05-25 | 四川大学 | 用于治疗的抗肿瘤和抗真菌化合物 |
| WO2016179702A1 (en) * | 2015-05-11 | 2016-11-17 | Ranju Ralhan | Acridinone compositions for treating head and neck cancers and methods of prognosing head and neck cancers |
| US11938128B2 (en) | 2017-03-10 | 2024-03-26 | Albert Einstein College Of Medicine | Small molecule BAX inhibitors and uses thereof |
-
2018
- 2018-11-20 AU AU2018368789A patent/AU2018368789B2/en not_active Ceased
- 2018-11-20 CN CN201880086600.0A patent/CN111630036B/zh active Active
- 2018-11-20 CA CA3079262A patent/CA3079262A1/en active Pending
- 2018-11-20 KR KR1020207017927A patent/KR20200100081A/ko not_active Ceased
- 2018-11-20 JP JP2020545072A patent/JP7323539B2/ja active Active
- 2018-11-20 WO PCT/US2018/062021 patent/WO2019100061A1/en not_active Ceased
- 2018-11-20 US US16/195,997 patent/US10745358B2/en active Active
- 2018-11-20 BR BR112020009592-3A patent/BR112020009592A2/pt not_active IP Right Cessation
- 2018-11-20 SG SG11202004442VA patent/SG11202004442VA/en unknown
- 2018-11-20 EP EP18878928.3A patent/EP3713920A4/en active Pending
- 2018-11-20 MX MX2020004902A patent/MX2020004902A/es unknown
-
2020
- 2020-05-15 PH PH12020550652A patent/PH12020550652A1/en unknown
- 2020-05-20 IL IL274796A patent/IL274796A/en unknown
-
2022
- 2022-07-28 US US17/875,770 patent/US20230113570A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| US20230113570A1 (en) | 2023-04-13 |
| WO2019100061A1 (en) | 2019-05-23 |
| SG11202004442VA (en) | 2020-06-29 |
| EP3713920A1 (en) | 2020-09-30 |
| JP7323539B2 (ja) | 2023-08-08 |
| PH12020550652A1 (en) | 2021-04-26 |
| CN111630036A (zh) | 2020-09-04 |
| IL274796A (en) | 2020-07-30 |
| KR20200100081A (ko) | 2020-08-25 |
| CA3079262A1 (en) | 2019-05-23 |
| US20190161449A1 (en) | 2019-05-30 |
| BR112020009592A2 (pt) | 2020-11-03 |
| AU2018368789A1 (en) | 2020-06-11 |
| EP3713920A4 (en) | 2021-04-14 |
| AU2018368789B2 (en) | 2022-06-02 |
| CN111630036B (zh) | 2024-12-27 |
| JP2021503501A (ja) | 2021-02-12 |
| US10745358B2 (en) | 2020-08-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2020004902A (es) | Derivados del acido oxoacridinilo acetico y metodos de uso. | |
| DOP2019000005A (es) | 3-metil pirazinas 2,5-disustituidas y 3-metil pirazinas 2,5,6-trisustituidas como inhibidores alostéricos de shp2 | |
| MX2022013010A (es) | Composiciones y metodos para inhibir la expresion genica de lpa. | |
| CL2018003681A1 (es) | Derivados de ácido borónico y usos terapéuticos de los mismos | |
| CU20160087A7 (es) | Indazolcarboxamidas, procedimientos para su preparación, preparaciones farmacéuticas que las contienen | |
| MX2017016344A (es) | Compuestos de benzoxacepina oxazolidinona y metodos de uso. | |
| CO7160104A2 (es) | Inhibidores de virus de hepatitis c | |
| BR112015023760A2 (pt) | compostos e composições terapêuticas | |
| MX2017007489A (es) | Tetrahidro-pirido[3,4-b]indoles moduladores de receptores de estrógenos y usos de los mismos. | |
| EA201790576A1 (ru) | Спироциклические ингибиторы катепсина с | |
| EA201500207A1 (ru) | Гетероароматические соединения в качестве ингибиторов втк | |
| MX385367B (es) | Esteres de acidos grasos de cadena media de beta-hidroxibutirato y butanodiol y composiciones y metodos para usar los mismos. | |
| ECSP12012174A (es) | Derivados de n-(imidazopirimidin-7-il)-heteroarilamida y su uso como inhibidores de pde10a | |
| MX2017004129A (es) | Derivado de acido 4-(4-(4-fenilureido-naftalen-1-il)oxi-piridin-2- il)amino-benzoico como inhibidor de quinasa p38. | |
| UY35827A (es) | Derivados de triazolopirazina como inhibidores de la proteína brd4 | |
| EA201390347A1 (ru) | Лечение заболеваний | |
| CY1120515T1 (el) | Παραγωγο κυκλοαλκυλικο οξεος, μεθοδος παρασκευης και φαρμακευτικη εφαρμογη αυτου | |
| CO2017000980A2 (es) | Compuestos derivados de imidazo[1,2-b]piridazin-2-carboxamida e imidazo[1,2- b]piridazin-2-ilmetanona activos como inhibidores selectivos de la fosfodiesterasa 4a (pde4a) | |
| CU20160140A7 (es) | CROMENE Y 1,1 A,2,7B- tetrahidrociclopropa[C]CROMENE PIRIDOPIRAZINEDIONES COMO MODULADORES DE GAMMA-SECRETASA | |
| MX2022007178A (es) | Compuestos heterociclicos como moduladores del estimulador de genes de interferon (sting). | |
| UY29639A1 (es) | Amidas sustituidas con heteroarilo que comprenden un grupo enlazador insaturado o cíclico, y su uso como productos farmacéuticos | |
| CO2018001359A2 (es) | Derivados del ácido 5-(n-bencil-tetrahidroisoquinolin-6-il)-piridin-3-il acético como inhibidores de la replicación del virus de la inmunodeficiencia humana | |
| UY33490A (es) | Ésteres de quinolina nuevos útiles para el tratamiento de trastornos cutáneos. | |
| UY33874A (es) | Derivados de ácido 3-heteroaroilamino-propiónico sustituidos y su uso como sustancias farmacéuticas | |
| EP4003323A4 (en) | STABILIZED FORMULATIONS OF 4-AMINO-3-SUBSTITUTED BUTANOIC ACID DERIVATIVES |